Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 26;44(1):19.
doi: 10.1007/s10555-024-10238-y.

Homologous recombination deficiency (HRD) diagnostics: underlying mechanisms and new perspectives

Andrey Kechin  1   2 , Maksim Koryukov  3   4 , Regina Mikheeva  3   4 , Maksim Filipenko  3
Affiliations
Review

Homologous recombination deficiency (HRD) diagnostics: underlying mechanisms and new perspectives

Andrey Kechin et al. Cancer Metastasis Rev. .

Abstract

Homologous recombination deficiency (HRD) is considered a universal and effective sign of a tumor's sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors. HRD diagnostics have undergone several stages of transformations: from detection of point mutations in HR-related genes and large regions with loss of heterozygosity detected using single-nucleotide polymorphism arrays to whole-genome signatures of single-nucleotide variants, large genomic rearrangements (LGRs), and copy number alterations. All these methods have their own advantages and limitations. HRD tests, based on signatures of LGRs and copy number alterations, show in hindsight that some progenitor cells have possessed HRD status but not the current state of the genome. The aim of this review was to compare different methods of HRD detection and mechanisms of formation of HRD-specific LGRs. In the last several years, new data appeared implying a crucial role of proteins BRCA1 and BRCA2 in the resolution of stalled replication forks that may be associated with at least some of LGRs observed in HRD-positive tumors. Reviewing current knowledge on these mechanisms, distributions of different LGR types, and limitations of sequencing technologies and algorithms of data analysis, we offer some new perspectives on HRD diagnostics. We hope that this review will help to accelerate the development of new diagnostic approaches in this important field of molecular oncology.

Keywords: BRCA1; BRCA2; Cancer; PARP inhibitor; Replication restart.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

References

    1. Nguyen, L., W. M. Martens, J., Van Hoeck, A., & Cuppen, E. (2020). Pan-cancer landscape of homologous recombination deficiency. Nature Communications 2020 11:1, 11(1), 1–12. https://doi.org/10.1038/s41467-020-19406-4
    1. Eeckhoutte, A., Houy, A., Manié, E., Reverdy, M., Bièche, I., Marangoni, E., Popova, T. (2020). ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing. Bioinformatics, 36(12), 3888. https://doi.org/10.1093/BIOINFORMATICS/BTAA261
    1. Pepe, F., Guerini-Rocco, E., Fassan, M., Fusco, N., Vacirca, D., Ranghiero, A., Iaccarino, A. (2023). In-house homologous recombination deficiency testing in ovarian cancer: A multi-institutional Italian pilot study. Journal of clinical pathology. https://doi.org/10.1136/JCP-2023-208852
    1. Wu, Y., Xu, S., Cheng, S., Yang, J., & Wang, Y. (2023). Clinical application of PARP inhibitors in ovarian cancer: From molecular mechanisms to the current status. Journal of Ovarian Research, 16(1), 1–15. https://doi.org/10.1186/S13048-023-01094-5/TABLES/2 - DOI - PubMed - PMC
    1. Lin, C., Liu, P., Shi, C., Qiu, L., Shang, D., Lu, Z., Liu, H. (2023). Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers. Fundamental & clinical pharmacology, 37(2), 194–214. https://doi.org/10.1111/FCP.12834

LinkOut - more resources